How RenovoRx’s TAMP platform data could reshape intra-arterial drug delivery in pancreatic cancer
RenovoRx’s ASCO 2026 data highlights how targeted gemcitabine delivery could reshape pancreatic cancer treatment strategy. Read more.
Could RenovoRx be building a stronger medtech oncology moat through global patent expansion?
Could RenovoRx’s Japan patent strengthen the RenovoCath oncology moat? Read the full PDN analysis on commercial risks, adoption, and global expansion.